New pill takes on three tough cancers in early human test

NCT ID NCT06966024

Recruiting now Disease control Sponsor: Deciphera Pharmaceuticals, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new oral drug called DCC-2812 in 60 people with advanced kidney, bladder, or prostate cancers that have spread. The main goals are to check safety and find the right dose, while also looking for signs that the drug can shrink tumors. It is a first step to see if this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DCC-2812
What this could lead to: If it works, this could point toward a new treatment option for advanced kidney, bladder, or prostate cancers that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 60 people, so it is primarily checking safety. The drug may not shrink tumors or may cause side effects that limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma renal cell carcinoma transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER RENAL CELL CARCINOMA UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
NEXT Oncology, Austin
RECRUITING

Austin, Texas, 78758, United States
NEXT Oncology, San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Email: •••••@•••••
Vanderbilt- Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.